Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Lifts Boston Scientific Warning Letter Restrictions On PMA Approvals

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific anticipates FDA approval of its Express SD renal stent, among other products, now that the agency has lifted the restrictions on Class III device approvals imposed by a 2006 company-wide warning letter
Advertisement

Related Content

Boston Scientific’s Express SD Renal Stent Gains FDA Approval
Boston Scientific’s Express SD Renal Stent Gains FDA Approval
Boston Scientific’s Taxus Liberté approved
Advertisement
UsernamePublicRestriction

Register

MT026715

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel